SCHEMBL24769797

SCHEMBL24769797

CCOC(O)OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.43
SLC1A2 P43004 2/20 0.43
SLC1A1 P43005 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
TSHR P16473 2/20 0.43
ALDH1A1 P00352 2/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
RCE1 Q9Y256 1/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18697922 0.81 RCE1 (0.43) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
Bromide SCHEMBL29142495 0.80 RCE1 (0.49) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL10720994 0.79 SLC1A3 (0.44) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL28528176 0.79 THRB (0.48) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL4849161 0.78 CA1 (0.46) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL4186836 0.78 ALDH1A1 (0.48) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL345617 0.78 CA1 (0.46) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL28606866 0.78 LMNA (0.50) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL6005456 0.77 SLC1A3 (0.41) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL5751604 0.77 KMT2A (0.53) SLC1A3SLC1A2SLC1A1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402881-A1 SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS ALBERT EINSTEIN COLLEGE OF MEDICINE 2022-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402881-A1 SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS PTGER1, PTGIS, PTGIR SLC1A3 303/4885SLC1A2 265/4885SLC1A1 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.